Browsing by Author "Aarsland, D. (56222844000)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study(2016) ;Biundo, Roberta (8859828200) ;Weis, L. (55617107600) ;Bostantjopoulou, S. (55977734100) ;Stefanova, E. (7004567022) ;Falup-Pecurariu, C. (26535634100) ;Kramberger, M.G. (36544238400) ;Geurtsen, G.J. (57062897200) ;Antonini, A. (7102486937) ;Weintraub, D. (57203216133)Aarsland, D. (56222844000)The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects. © 2016, Springer-Verlag Wien. - Some of the metrics are blocked by yourconsent settings
Publication MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study(2016) ;Biundo, Roberta (8859828200) ;Weis, L. (55617107600) ;Bostantjopoulou, S. (55977734100) ;Stefanova, E. (7004567022) ;Falup-Pecurariu, C. (26535634100) ;Kramberger, M.G. (36544238400) ;Geurtsen, G.J. (57062897200) ;Antonini, A. (7102486937) ;Weintraub, D. (57203216133)Aarsland, D. (56222844000)The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are the most commonly used scales to test cognitive impairment in Lewy body disease (LBD), but there is no consensus on which is best suited to assess cognition in clinical practice and most sensitive to cognitive decline. Retrospective cohort study of 265 LBD patients [Parkinson’s disease (PD) without dementia (PDnD, N = 197), PD with dementia (PDD, N = 40), and dementia with Lewy bodies (DLB, N = 28)] from an international consortium who completed both the MMSE and MoCA at baseline and 1-year follow-up (N = 153). Percentage of relative standard deviation (RSD%) at baseline was the measure of inter-individual variance, and estimation of change (Cohen’s d) over time was calculated. RSD% for the MoCA (21 %) was greater than for the MMSE (13 %) (p = 0.03) in the whole group. This difference was significant only in PDnD (11 vs. 5 %, p < 0.01), but not in PDD (30 vs. 19 %, p = 0.37) or DLB (15 vs. 14 %, p = 0.78). In contrast, the 1-year estimation of change did not differ between the two tests in any of the groups (Cohen’s effect <0.20 in each group). MMSE and MoCA are equal in measuring the rate of cognitive changes over time in LBD. However, in PDnD, the MoCA is a better measure of cognitive status as it lacks both ceiling and floor effects. © 2016, Springer-Verlag Wien. - Some of the metrics are blocked by yourconsent settings
Publication Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators(2024) ;Jessen, Frank (7006672877) ;Kramberger, M.G. (36544238400) ;Angioni, D. (57218317683) ;Aarsland, D. (56222844000) ;Balasa, M. (36668211900) ;Bennys, K. (6507192782) ;Boada, M. (57192408353) ;Boban, M. (56186239100) ;Chincarini, A. (55885268100) ;Exalto, L. (26658986600) ;Felbecker, A. (35746236900) ;Fliessbach, K. (6506812066) ;Frisoni, G.B. (56214208300) ;Garza-Martínez, A.J. (57394406400) ;Grimmer, T. (6507487659) ;Hanseeuw, B. (35114773100) ;Hort, J. (15020481600) ;Ivanoiu, A. (57219106513) ;Klöppel, S. (23100462800) ;Krajcovicova, L. (24724610700) ;McGuinness, B. (57192408447) ;Mecocci, P. (7006313835) ;de Mendonca, A. (55307490700) ;Nous, A. (57216750798) ;Ousset, P.-J. (7003951573) ;Paquet, C. (23502231800) ;Perneczky, R. (57209088266) ;Peters, O. (57204202580) ;Tabuas-Pereira, M. (56493155900) ;Piazza, F. (57863283300) ;Plantone, D. (26538821100) ;Riverol, M. (24462200800) ;Ruiz, A. (7203006899) ;Sacco, G. (55556226500) ;Santana, I. (6603922366) ;Scarmeas, N. (6701754861) ;Solje, E. (56232842500) ;Stefanova, E. (7004567022) ;Sutovsky, S. (22952529500) ;van der Flier, W. (8548678900) ;Welsh, T. (55820604800) ;Wimo, A. (56235097300) ;Winblad, B. (36048831500) ;Frölich, L. (56820309600)Engelborghs, S. (7004850774)β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer’s disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer’s Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now. Given the complexity of AD it is unlikely that molecular single-target treatments will achieve substantially larger effects than those seen with current β-amyloid-targeting antibodies. Larger effects will most likely only be achieved incrementally by continuous optimization of molecular approaches, patient selection and combinations therapies. To be successful in this regard, drug development must be informed by the use of innovative treatments in real world practice, because full understanding of all facets of novel treatments requires experience and data of real-world care beyond those of clinical trials. Regarding the antibodies under discussion we consider their effects meaningful and potential side effects manageable. We assume that the number of eventually treated patient will only be a fraction of all early AD patients due to narrow eligibility criteria and barriers of access. We strongly endorse the use of these new compound in clinical practice in selected patients with treatment documentation in registries. We understand this as a critical step in advancing the field of AD treatment, and in shaping the health care systems for the new area of molecular-targeted treatment of neurodegenerative diseases. © The Authors 2024.
